Eur J Clin Microbiol Infect Dis by Zhou, F. F. et al.
Clinical characteristics of Clostridium difficile infection in 
hospitalized patients with antibiotic-associated diarrhea in a 
university hospital in China
F. F. Zhou,
Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China
S. Wu,
Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China
J. D. Klena, and
Global Disease Detection Branch, Division of Global Health Protection, Center for Global Health, 
Centers for Disease Control and Prevention, Atlanta, GA, USA
H. H. Huang
Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China
H. H. Huang: drhaihuihuang@163.com
Abstract
The purpose of this study was to identify clinical characteristics of Clostridium difficile infection 
(CDI) in patients with antibiotic-associated diarrhea (AAD). A prospective study was conducted 
among patients hospitalized in Fudan University Hospital Huashan from August 1, 2012 to July 
31, 2013. Toxigenic C. difficile isolates were characterized by PCR ribotyping and multilocus 
sequence typing. AAD developed in 1.0 % (206/20437) of the antibiotic-treated hospitalized 
patients and toxigenic C. difficile was isolated from 30.6 % (63/206) of patients with AAD. The 
frequency of AAD was highest in the intensive care unit (10.7 %); however the proportion of CDI 
in AAD was highest in the Geriatric Unit (38 %). AAD ranged in severity from mild to moderate. 
One case with pseudomembranous colitis was identified. Use of carbapenems was found to 
significantly increase the risk of CDI (OR, 2.31; 95 % CI, 1.22–4.38; p= 0.011). Patient 
demographics, presumed risk factors, clinical manifestations and laboratory findings revealed no 
significant difference between patients with CDI and non-C. difficile AAD. Over 90 % of the 
patients with CDI or non-C. difficile AAD were cured. Two patients had CDI recurrence. Ribotype 
H was the dominant (18.8 %) genotype, followed by ribotype 012 and ribotype 017. C. difficile 
plays a significant role in AAD in our setting in China. Because the severity of diarrhea ranges 
from mild to moderate, it is difficult for Chinese clinicians to identify CDI from AAD patients, 
therefore CDI should be included in the routine differential diagnoses for hospitalized patients 
presenting with AAD.
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Antibiotic-associated diarrhea (AAD) is described as diarrhea that occurs in conjunction 
with antibiotic administration and cannot be explained by another diagnosis. AAD can range 
from a mild, self-limiting illness to more serious and progressive disease such as 
pseudomembranous colitis (PMC) [1]. AAD results from overgrowth of the intestinal 
mucosa by pathogenic microorganisms after antibiotic treatment; however, it may also occur 
in response to a reduction in the concentration of fecal flora. This can lead to a decrease in 
carbohydrate metabolism which in turn causes osmotic diarrhea and a decreased rate of 
primary bile acid breakdown [2].
Clostridium difficile has been linked to AAD since 1977. However, since the early 2000s, 
the incidence and severity of C. difficile infection (CDI) have increased dramatically in 
North America and Europe [3, 4]. C. difficile is the most important infectious cause of AAD, 
accounting for 10–30 % of all cases; when considering severe cases of AAD such as 
documented antibiotic-associated PMC, 90–100 % are attributed to CDI [2, 5]. Although 
other organisms, including Clostridium perfringens, Staphylococcus aureus and Klebsiella 
oxytoca, may cause AAD, they are not common [6].
European guidelines for treatment of CDI recommend that patients with mild-to-moderate 
CDI should be treated with metronidazole and patients with severe CDI should be treated 
with vancomycin; anti-peristaltic agents are contraindicated [4]. In contrast, for the 
treatment of AAD from other causes, anti-peristaltic agents are often used and 
metronidazole or vancomycin is not indicated [5]. Therefore it is important for clinicians to 
correctly diagnose a CDI case, not only for successful treatment, but also to decrease 
unnecessary use of metronidzole and/or vancomycin.
Although CDI is recognized as a major epidemic organism in North America and Europe, 
data from China remain limited. A prospective, observational study was conducted to 
evaluate the clinical characteristics of CDI in patients with AAD at University Hospital 
Huashan, a 1,216-bed hospital from August 1, 2012 to July 31, 2013 and to raise awareness 
of this disease in China.
Materials and methods
Definitions
Diarrhea was defined as three or more loose stools (corresponding to Bristol stool chart 
types 5–7) in≥24 h or more frequently than is normal for the individual case. A case of AAD 
was defined as otherwise unexplained diarrhea in a hospitalized patient occurring in 
association with the administration of antibiotics [1]. A case-patient with CDI was defined 
as a positive toxigenic C. difficile culture from a diarrhea hospitalized patient, or PMC 
diagnosed during enteroscopy. We defined diarrhea as severe when it occurred with one or 
more of the following: visible blood in the stool, fever (T> 38.0 °C) and leukocytosis 
(>12.0×109/l), hypoalbuminemia (<20 g/l) or PMC. A complicated course of CDI was 
defined as either an admission to the intensive care unit (ICU), a surgical intervention in 
association with CDI or death within one month of diarrhea onset. Mortality was considered 
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to be attributable to CDI when a patient died during admission, partly due to the 
consequences of CDI [7]. Patients were followed until hospital discharge. Two episodes in 
the same patient were considered different events if they occurred ≥8 weeks apart.
Patients
Eligibility criteria included being a hospitalized patient aged ≥18 years with acute diarrhea, 
and receiving antibiotic treatment ≥4 weeks before the onset of diarrhea. Patients with 
chronic diarrhea or who had history of using a laxative within 3 days preceding diarrhea 
onset were excluded. The study was approved by the Institutional Review Board at Fudan 
University Hospital Huashan.
C. difficile isolates
All fecal specimens from qualified patients were cultured on selective cycloserine–
cefoxitin–fructose agar plates (Oxoid, Basingstoke, UK) and incubated in an anaerobic 
chamber (Ruskinn Technology Limited, Bridgend, UK) at 37ºC for 72 h. C. difficile 
colonies were identified on the basis of their typical morphology on agar plates, Gram stain 
and Rapid ID 32A identification test strips (BioMérieux, Marcy l’Etoile, France). The tcdA 
gene was detected by conventional PCR [8]. Multiplex real-time PCR to detect tcdB and 
cdtA genes was performed using the Cepheid Xpert™ C. difficile assay (Cepheid, Sunny 
Vale, CA, USA). Toxin B was confirmed by the cytotoxicity neutralization assay (Techlab, 
Blacksburg, VA, USA) with Vero cell lines. Strains were characterized further by ribotyping 
[9] and multilocus sequence typing (MLST) (http://pubmlst.org/cdifficile/) [10].
Clinical characteristics
A questionnaire was completed for each patient. The following data were collected: 
demographic data (e.g., age, gender, ward, community versus hospital acquisition, 
comorbidity), presumed risk factors in the 4 weeks before the onset of diarrhea (e.g., 
antimicrobial treatment, chemotherapy, naso-gastric intubation, surgery), biological 
parameters (e.g., albumin, white blood cell count [WBC]), and clinical course (e.g., severity, 
clinical and laboratory findings, treatment, and outcome) [11, 12].
Statistical analysis
SPSS version 16.0 (SPSS, Cary, NC, USA) was used for statistical analyses. To preserve the 
assumption of the independence of the observations, only the first episode of CDI for an 
individual patient was included in the analysis. The chi-square or Fisher’s exact test was 
applied to compare categorical variables. The level of statistical significance was defined as 
p<0.05. Predictors of CDI were investigated using a logistic regression analysis. Age, sex 
and location were adjusted for multivariate analysis. Odds ratios and 95 % confidence 
intervals were used to quantify the strength of these associations.
Results
During the one-year study period, 46,558 patients were discharged from the University 
Hospital Huashan; 20,437 patients had received at least one dose of antibiotic. AAD 
developed in 1.0 % (206/20,437) of the treated patients and toxigenic C. difficile was 
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isolated from 30.6 % (63/206) of patients with AAD. The frequency of AAD was highest in 
the intensive care unit (ICU) (10.7 %, 56/525) (Fig. 1); however, the proportion of CDI in 
AAD cases was highest in the geriatric unit (38 %, 11/29). In total, 65 C. difficile isolates 
(63 from the first episode and two from recurrence) were recovered but one was not 
retrievable upon subculture. Eighteen different ribotypes were identified; ribotype H (ST-81, 
18.8 %) was the most prevalent, followed by 012 (ST-54, 14.1 %) and 017 (ST-37, 12.5 %). 
None of the isolates belonged to ribotype 027 (ST-1) or 078 (ST-11).
Clinical characteristics and risk factors
Clinical characteristics and risk factors for CDI and nonC. difficile AAD are summarized in 
Table 1. The mean age for CDI and non-C. difficile AAD case-patients were 66±17 and 
62±20 years old, respectively. Most of the case-patients were male. Diabetes mellitus and 
malignancy were the most common underlying diseases in both groups. Beta-lactamase 
inhibitors were the most commonly prescribed class of antibiotic in both groups of patients 
(44.4 and 55.2 %, respectively). Carbapenems were prescribed significantly more frequently 
in case-patients with CDI than those with nonC. difficile AAD (42.9 % vs.28.0 %, p=0.036). 
After univariate analysis and using a multivariate logistic regression model, only the use of 
carbapenems was found to be significantly associated with increased risk of CDI (RR, 2.31; 
95 % CI, 1.22–4.38; p=0.011).
Clinical course
Neither fever (44.4 % vs. 33.6 %), abdominal pain (11.1 % vs. 7.7 %), nor WBC count 
showed significant differences between CDI and non-C. difficile AAD case-patients (Table 
1). The results of diarrheal stool examinations were similar in both groups as well. Among 
patients who had received a stool examination, WBC were present in 10 % (5/50) and 4.0 % 
(4/99) diarrheal stool samples with CDI and non-C. difficile AAD (p=0.385), respectively. 
Red blood cells (RBC) were present in 4 % (2/50) and 1.0 % (1/99) of diarrheal stool 
samples of patients from both groups (p=0.220), respectively. Only one patient presented 
with PMC. The severity of other patients with CDI or non-C. difficile AAD ranged from 
mild to moderate diarrhea.
Once diagnosed as AAD, clinicians withdrew the implicated antibiotic from the treatment 
regime of the majority of patients (Table 2). Twenty-three of the 63 case-patients with CDI 
(36.5 %) received specific empirical treatment. Metronidazole was used in 10 (15.9 %) case-
patients, but was changed to oral vancomycin in four case-patients because of a lack of 
clinical response at 10.5±6.6 days of treatment. Oral vancomycin was initially used in 13 
case-patients. Among patients with non-C. difficile AAD, only five patients received 
vancomycin and three patients received metronidazole respectively (p<0.001). Almost 40 % 
of patients received probiotics in both groups, including Bacillus bifidus, Lactobacillus 
acidophilus and Enterococcus spp. In addition, more case-patients with CDI received 
berberine, a traditional Chinese medicine, than patients with non-C. difficile AAD (39.7 % 
vs. 17.5 %, p=0.001). In total, 85.7 % (54/63) and 92.3 % (132/ 143) of patients with CDI or 
non-C. difficile AAD, respectively, were cured. Two case-patients experienced one episode 
of CDI recurrence. Three patients died, one in the CDI group and two patients in the non-C. 
difficile AAD group. However, AAD did not contribute to these deaths.
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Diarrhea is one of the most frequent side effects of antibiotic therapy in hospitalized 
patients, occurring in 5–25 % of all patients [13]. The frequency of AAD depends on the 
antibiotics used for treatment as well as host-specific factors. In Sweden, Wiström et al. [14] 
reported the frequency of AAD varied from 1.8 to 6.9 % in participating centers in a large 
prospective study. The percentage of AAD cases reported in China is higher. Chen et al. 
[15] reported the frequency of AAD at 9.3 % (78/842) among patients hospitalized in a 
Chinese medical unit from 2002 to 2005, and Wang et al. [16] reported that the frequency of 
AAD among patients hospitalized in a Chinese digestive unit was 6.7 % (26/423) in 2007. In 
the present study, of the 20,437 antibiotic-treated patients, only 1.0 % developed AAD. One 
reason that the percentage of cases in this study with AAD is lower than expected might be 
the number of treated patients from surgical wards is more than two times that from medical 
wards (13,684 vs. 6,228). Most of the patients from the surgical wards received antibiotics 
for peri-operative prophylaxis only. In addition, clindamycin, which is related to a higher 
frequency of diarrhea, has not been used in the University Hospital Huashan setting since 
2009.
C. difficile has been reported to account for approximately 20–30 % of all cases of AAD and 
is responsible for most antibiotic-related colitis (AAC) [2, 5]. As the incidence of CDI has 
increased in North America and Europe, some Chinese clinicians have expressed concern 
about the situation in China. Chen et al. [17] tested 1,845 diarrheal stool samples submitted 
to the clinical microbiology laboratory of a tertiary hospital in China and 161 (8.7 %) 
toxigenic C. difficile isolates were recovered between 2009 and 2011. Similarly, Hawkey et 
al. examined fecal samples from 70 hospital patients with diarrhea who were receiving or 
had received antibiotics within the previous six weeks in a separate Chinese tertiary hospital; 
21 (30 %) C. difficile isolates were recovered [18]. In the present study, the CDI was 
detected in 30.6 % of 206 patients with AAD, a result consistent with Hawkey et al.
Patients who are likely to develop clinically significant AAD are at high risk for CDI. 
Antibiotic use itself is the most important risk factor for the development of CDI. Virtually 
all antibiotics have been implicated in CDI and AAD. Clindamycin, cephalosporins, and 
extended-spectrum penicillins are the antibiotics most frequently associated with CDI, 
although they also cause diarrhea that is unrelated to superinfection with this organism. 
Recently, fluoroquinolones such as moxifloxacin have been implicated as a common cause 
of CDI [5, 19–21]. In contrast, erythromycin acts as a motilin-receptor agonist and 
accelerates the rate of gastric emptying. This scenario is more likely to result in non-C. 
difficile AAD [6]. In the present study clindamycin was not used and only two patients with 
non-C. difficile AAD had previously received azithromycin. Compared with non-C. difficile 
AAD, only previous use of a carbapenem antibiotic was determined to be an independent 
risk factor for development of CDI. Carbapenems have the broadest spectrum of activity 
within the β-lactam class of antibiotics, and therefore it is reasonable to assume that they 
have a stronger propensity to disrupt normal intestinal microflora. Asha et al. [6] reported 
that despite the use of different control groups, symptomatic patients without infected AAD 
or asymptomatic hospitalized patients, the risk factors for CDI identified in their study were 
broadly similar. However, other well-known risk factors for CDI including being elderly, 
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impaired immune status, length of hospital stay, infected roommates, and nasogastric tube 
feeding [20, 21] were not identified as risk factors in the present study. This may be because 
with the exception of a single PMC patient, the severity of CDI was similar to that of non-C. 
difficile AAD, ranging from mild to moderate diarrhea. It is also possible that due to the low 
frequency of AAD and CDI cases, the methods used in this study were not sensitive enough 
to identify additional risk factors.
Clinical presentation has been used to distinguish between CDI and AAD due to other 
causes. Typically, other causes of AAD result in less severe disease than CDI. Patients with 
CDI may have evidence of colitis with abdominal cramps, low-grade fever, and fecal 
leukocytes; however, patients with diarrhea from other causes usually present with 
moderately severe diarrhea without evidence of colitis. Complications reported for CDI 
include hypoalbuminemia, anasarca, and toxic megacolon; non-CDI AAD is generally 
uncomplicated, with occasional cases of dehydration [2, 5, 19]. In the present study, no 
significant difference in clinical presentation was found between the two groups. This 
finding is consistent with previous studies in China [15, 17, 22] and helps to explain why 
CDI has been seriously underestimated in China as well. Clinicians do not effectively 
diagnose CDI based on the more mild presentation.
According to the guidelines published by the United States and European countries, 
metronidazole and vancomycin are recommended for treatment of CDI [4, 23]. Resolution 
of AAD symptoms other than C. difficile can usually be achieved through discontinuation of 
the offending antibiotic [5, 19]. In the present study 36.5 % of the patients with CDI 
received metronidazole and/or vancomycin compared to 5.6 % patients with non-C. difficile 
AAD. The reasons could be the clinical manifestation of CDI and AAD were similar in the 
present study and a lack of routine testing for C. difficile in clinical laboratory. Therefore it 
is difficult for clinicians to identify a CDI case from AAD. Berberine, a traditional plant 
alkaloid isolated from many kinds of plants such as Hydrastis canadensis, Berberis aristata 
and Coptis chinensis, has been used in treatment of gastroenteritis, abdominal pain and 
diarrhea in Ayurvedic, Chinese and Middle Eastern folk medicine for centuries [24]. It has 
been shown to have anti-inflammatory and antimicrobial properties [24, 25]. In addition, it 
is thought to be poorly absorbed through the gut wall and therefore is present in high 
concentrations in the stool [26]. In the present study, berberine was prescribed in 39.7 % and 
17.5 % of patients with CDI and non-C. difficile AAD, with cure rates of 84 % and 92.0 %, 
respectively. A meta-analysis concluded that the therapeutic effects of pure traditional 
Chinese medicine (TCM) or a combination of TCM and Western medicine for treatment of 
AAD were superior to the effects of Western medicine alone [27]. Shu et al. [28] reported 
the inhibition of expression of C. difficile toxin genes was a potential pharmacological 
pathway of TCM for the treatment of CDI. Further studies are clearly required.
Our previous studies [9, 22] reported that C. difficile ribotype 017 was the dominant clone in 
University Hospital Huashan between 2007 and 2009. However, in the present study another 
clone, ribotype H (ST-81, 18.8 %) became dominant, followed by ribotype 012 (ST-54, 14.1 
%). Ribotype 017 (ST-37, 12.5 %) had been displaced to third most prevalent. In China, Yan 
et al. in Beijing [29] reported ST-37 (24.0 %), ST-35 (15.4 %) and ST-54 (11.5 %) while 
Chen et al. in Hangzhou [17] reported ST-54 (23.0 %), ST-35 (19.3 %) and ST-37 (10.0 %) 
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as the top three prevalent genotypes, respectively. This diversity is likely due to the different 
geographical location. Recovery of C. difficile ribotype 027 is rare in Asia. At University 
Hospital Huashan, ribotype 027 has not been recovered. However, in late 2013, Wang et al. 
[30] reported the identification of a C. difficile ribotype 027 isolate in mainland China for 
the first time. Since this hypervirulent strain has spread rapidly in North America and 
Europe and is associated with many outbreaks, Chinese health workers must become highly 
vigilant.
A limitation of this study is that University Hospital Huashan is a tertiary care hospital, and 
thus receives many referrals, including patients from all over China. This fact makes it very 
difficult to perform follow-up studies with the patients. Therefore the recurrence rate is 
likely to be an underestimate.
In conclusion, C. difficile plays an important role in AAD in China. It is difficult for 
clinicians to identify CDI cases based on clinical presentation of AAD patients since the 
severity of disease ranges from mild to moderate diarrhea. Therefore, C. difficile infections 
should be included in the routine differential diagnoses for hospitalized patients with 
diarrhea, especially AAD. With the recent discovery of the first ribotype 027 cases in China, 
national surveillance is crucial to monitor the incidence, identify populations at risk, and 
characterize the molecular epidemiology of the strains causing CDI.
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(AAD) diarrhea in hospitalized patients who had received prior antibiotic therapy
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Table 1
Univariate and multivariate analyses of development of Clostridium difficile infection (CDI) compared with 
patients with non-Clostridium difficile antibiotic-associated diarrhea (non-C. difficile AAD)





Crude odds ratio (95 % 
CI)
Adjusted odds ratio (95 % 
CI)
Age≥65 years 30 (47.6) 59 (41.3) 1.29 (0.71–2.35) 1.17 (0.64–2.16)
Male sex 39 (61.9) 89 (62.2) 0.99 (0.54–1.82) 0.97 (0.51–1.83)
Major comorbidities
 Chronic heart failure 2 (3.2) 0 NA NA
 Diabetes mellitus 28 (44.4) 59 (41.3) 1.14 (0.63–2.07) 1.16 (0.62–2.15)
 Gastrointestinal disease 26 (41.3) 48 (33.6) 1.31 (0.71–2.40) 0.95 (0.44–2.03)
 Malignancy 26 (41.3) 61 (42.7) 0.94 (0.52–1.72) 0.86 (0.45–1.63)
Predisposing factors 4 weeks preceding diagnosis
 Prior hospitalization 29 (46.0) 59 (41.3) 1.21 (0.67–2.21) 1.14 (0.61–2.13)
 Length of stay (≥7 days) 55 (87.3) 124 (86.7) 1.05 (0.43–2.55) 1.02 (0.41–2.53)
 Proton pump inhibitors 45 (71.4) 102 (71.3) 1.00 (0.52–1.94) 1.00 (0.51–1.97)
 Immunosuppressive agents 5 (7.9) 8 (5.6) 1.45 (0.46–4.64) 1.33 (0.41–4.34)
 Nasogastric tube 38 (60.3) 84 (58.7) 1.07 (0.58–1.95) 1.45 (0.74–2.86)
 Mechanical ventilation 9 (14.3) 23 (16.1) 0.87 (0.38–2.00) 1.51 (0.56–4.04)
 Dialysis 1 (1.6) 3 (2.1) 0.75 (0.08–7.38) 0.70 (0.07–7.08)
 Abdominal surgery 21 (33.3) 46 (32.2) 1.45 (NA) 6.71 (NA)
Antimicrobial treatment
 No. of antibiotics (≥3) 27 (42.9) 61 (42.7) 1.01 (0.55–1.84) 1.11 (0.60–2.06)
 Aminoglycosides 14 (22.2) 28 (19.6) 1.17 (0.57–2.42) 1.37 (0.64–2.92)
 Beta-lactamase inhibitor 28 (44.4) 79 (55.2) 0.65 (0.36–1.18) 0.77 (0.41–1.44)
 Carbapenems 27 (42.9) 36 (25.2) 2.23 (1.19–4.17) a 2.31 (1.22–4.38)a
Cephalosporins
 1st and 2nd generation 18 (28.6) 37 (25.9) 1.15 (0.59–2.22) 1.16 (0.57–2.37)
 3rd and 4th generation 18 (28.6) 33 (23.1) 1.33 (0.68–2.61) 1.17 (0.59–2.33)
 Fluoroquinolones 9 (14.3) 29 (20.3) 0.66 (0.29–1.48) 0.62 (0.27–1.42)
 Metronidazole 8 (12.7) 15 (10.5) 1.24 (0.50–3.10) 1.01 (0.39–2.60)
 Vancomycin 11 (17.5) 27 (18.9) 0.91 (0.42–1.97) 1.06 (0.48–2.35)
Biological markers at diagnosis
 WBC count >9.5×109/L 29 (46.0) 54 (37.8) 1.36 (0.75–2.48) 1.69 (0.90–3.19)
 Neutropenia (>75 %) 35 (55.6) 76 (53.1) 1.13 (0.62–2.07) 1.40 (0.74–2.66)
 Hypoalbuminemia (<35 g/L) 35 (55.6) 74 (51.7) 1.17 (0.64–2.11) 1.37 (0.73–2.57)
 Serum creatinine >195 μmol/L 3 (4.8) 7 (4.9) 0.96 (0.24–3.86) 1.07 (0.26–4.46)
a
Significant difference (p<0.05)
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Table 2
Treatment of patients with Clostridium difficile infection (CDI) and non-Clostridium difficile antibiotic-
associated diarrhea (non-C. difficile AAD)
Treatment No. (%) of patients Chi-square value P
CDI Non–C. difficile AAD
Discontinuation of implicated antibiotic 15 (23.8) 14 (9.8) 7.106 0.008
Metronidazole and/or vancomycin 23 (36.5) 8 (5.6) 32.692 0.000
Biotherapy 24 (38.1) 60 (42.0) 0.270 0.603
Biotherapy alone 7 (11.1) 31 (21.7) 3.246 0.072
Berberine 25 (39.7) 25 (17.5) 11.726 0.001
Berberine alone 7 (11.1) 10 (7.0) 0.980 0.322
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